|
Journal of Child and Adolescent Psychopharmacology
Age and Gender Effects on Olanzapine and Risperidone Plasma Concentrations in Children and Adolescents
To cite this article:
Wolfgang Aichhorn, Josef Marksteiner, Thomas Walch, Gerald Zernig, Hartmann Hinterhuber, Christoph Stuppaeck, Georg Kemmler.
Journal of Child and Adolescent Psychopharmacology.
November 2007,
17(5): 665-674.
doi:10.1089/cap.2006.0045.
Wolfgang Aichhorn, M.D.Department of Psychiatry and Psychotherapy, Private Medical University Salzburg, Salzburg, Austria. Josef Marksteiner, M.D.Department of General Psychiatry, Medical University Innsbruck, Innsbruck, Austria. Thomas Walch, M.D.Department of General Psychiatry, Medical University Innsbruck, Innsbruck, Austria. Gerald Zernig, M.D.Experimental Psychiatry Unit, Department of Psychiatry, Medical University Innsbruck, Innsbruck, Austria. Hartmann Hinterhuber, M.D.Department of General Psychiatry, Medical University Innsbruck, Innsbruck, Austria. Christoph Stuppaeck, M.D.Department of Psychiatry and Psychotherapy, Private Medical University Salzburg, Salzburg, Austria. Georg Kemmler Ph.D.Department of General Psychiatry, Medical University Innsbruck, Innsbruck, Austria. Background: Risperidone and olanzapine are second-generation antipsychotics that are increasingly used in child and adolescent psychiatry. So far, little is known about plasma concentrations and concentration-to-dose (C/D) ratios of these agents in children and adolescents compared to adults. Method: This study investigated whether age and gender influence risperidone and olanzapine plasma concentration by determining risperidone and olanzapine plasma levels by tandem mass spectrometry in 162 Caucasian patients (98 risperidone and 64 olanzapine). Results: For risperidone and 9-hydroxyrisperidone, the Ctotal/D ratio was almost identical in both age groups (10–18 and 19–45 years, respectively). In the younger age group, females exhibited significantly higher total plasma levels than males while receiving similar doses of risperidone. For olanzapine, in adolescents significantly higher C/D ratios were detected by an average of 43% (after adjustment for weight: 34%) compared to adults. Conclusion: This study demonstrates an age effect for olanzapine but not for risperidone resulting in higher olanzapine plasma levels in younger patients. For risperidone, we found a gender effect as female adolescent patients had significantly higher risperidone plasma concentrations than male adolescent patients. Future prospective studies are necessary to clarify whether the prescribed dosage should be different in young and older patients.  This paper was cited by:Olanzapine for the treatment of bipolar disorder in children and adolescents Jeffrey R Strawn, Melissa P DelBello Expert Opinion on Pharmacotherapy. Mar 2008, Vol. 9, No. 3: 467-474 CrossRef
|
|